# Optimal Dosage of Remifentanil for Vertebroplasty

> **NCT05876039** · PHASE4 · COMPLETED · sponsor: **Tri-Service General Hospital** · enrollment: 80 (actual)

## Conditions studied

- Remifentanil
- Analgesia

## Interventions

- **DRUG:** Initial remifentanil effect-site concentration

## Key facts

- **NCT ID:** NCT05876039
- **Lead sponsor:** Tri-Service General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-20
- **Primary completion:** 2024-08-24
- **Final completion:** 2024-12-27
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05876039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05876039, "Optimal Dosage of Remifentanil for Vertebroplasty". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05876039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*